
|Videos|October 14, 2021
Clinical Development Program Shows Promise for Microbiome-Based Therapeutics in Recurrent C. Diff
Lindy Bancke, PharmD, head of clinical development at Rebiotix Inc, said the clinical development program of RBX2660 is showing promise in the treatment of recurrent C. Difficile infection.
Advertisement
In an interview with Pharmacy Times, Lindy Bancke, PharmD, head of clinical development at Rebiotix Inc, said the clinical development program of RBX2660 is showing promise in the treatment of recurrent C. Difficile infection.
In the discussion, Bancke talked about how RBX2660 compared to previous treatment options, the link between the gut microbiome and C. diff, the impressive sustained clinical response success rate from the development program, and complementary findings from the PUNCH CD3 trial.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
3
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
4
Pharmacist Outreach Doubles SGLT2 Inhibitor Uptake in CKD
5





































































































